Phase I/II, multicenter, open-label study of intratumoral/intralesional administration of the retinoic acid-inducible gene I (RIG-I) activator MK-4621 in patients with advanced or recurrent tumors

Authors
Category Primary study
JournalAnnals of Oncology
Year 2018
This article has no abstract
Epistemonikos ID: af07a639e8da04d01ac3157b98729041645278eb
First added on: Feb 11, 2025